Development of anti-infliximab antibodies increases infliximab clearance in chronic Inflammatory Bowel Diseases.

Archive ouverte | Ternant, David | CCSD

Infliximab pharmacokinetics in inflammatory Bowel disease patients

Archive ouverte | Ternant, David | CCSD

International audience. Infliximab, a chimeric monoclonal antibody, has profoundly modified the treatment of several inflammatory diseases, but no satisfactory description of its pharmacokinetics is available. The o...

Development of anti-infliximab antibodies increases infliximab clearance in chronic inflammatory bowel disease

Archive ouverte | Ternant, David | CCSD

International audience